DaTSCAN 74 MBq/ml solution for injection
Sponsors
AC Immune S.A., Eip Pharma Inc., Biohaven Therapeutics Ltd.
Conditions
2017)Early Parkinson’s DiseaseEarly stages of idiopathic Parkinson's DiseaseSubjects aged ≥55 years with probable Dementia with Lewy Bodies DLB by consensus criteria (McKeith et albut the subject has historical polysomnography (PSG)-verified REM sleep behavioral disorder (RBD)including a positive DaTscan™ and a CDR Global Score of 0.5 or 1.0. If the DaTscan is negativethis will also qualify as probable DLB.
Phase 2
An adaptive, Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson’s disease
RecruitingCTIS2022-500292-31-00
Start: 2023-05-12Target: 121Updated: 2025-09-17
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
CompletedCTIS2023-504373-20-00
Start: 2023-08-09End: 2025-05-12Target: 15Updated: 2025-03-25
A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants with Early Parkinson’s Disease
Not yet recruitingCTIS2025-521113-13-00
Target: 713Updated: 2025-12-22